Evidence map›Paper›PMID 41888227›Full record

ArticleEJNMMI reports2026

Xueqin Zhao, Zhenzhen Wang, Xingyu Mu, Yang Wu, Jie Qin, ZuGuo Li, Wei Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xueqin ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Zhenzhen WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Xingyu MuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Yang WuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Jie QinDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
ZuGuo LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Wei FuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, China. fuwei19700513@163.com.ORCID http://orcid.org/0009-0000-5173-6331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlomus tumors (glomangiomas) are rare mesenchymal neoplasms derived from modified smooth muscle cells of the glomus body. Since they most commonly occur in the subungual regions of the extremities, primary involvement of the spine is exceedingly rare, particularly in atypical variants with borderline biological behavior. CASE PRESENTATION: A 61-year-old man presented with a long-standing history of intermittent back pain that had recently worsened. Magnetic resonance imaging revealed a solid lesion involving the T10-T11 vertebral region with intermediate T1 signal intensity, mildly hypointense T2 signal, intralesional hemorrhagic foci, and marked heterogeneous enhancement causing spinal canal stenosis.

conclusionThis case highlights the complementary role of MRI and

Indexed as

18F-FDG PET/CTAtypicalGlomus tumorMRISpine

Identifiers

PMID41888227
PMCPMC13022147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.